1. Introduction {#s0005}
===============

Recently Zhou et al. developed the new National Comprehensive Cancer Network (NCCN)- International Prognostic Index (IPI) to predict survival in the rituximab era more accurately than the older IPI system [@bib1]. Although reports that used the same prognostic stratification have since been published from various geographic regions, whether these results can be extrapolated to different ethnic populations is unclear. We therefore aimed to validate the NCCN-IPI in the presumably less selected population of Japanese patients with diffuse large B cell lymphoma (DLBCL).

2. Materials and methods {#s0010}
========================

We included 284 patients who were consecutively diagnosed with DLBCL and treated with first-line rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (*r*-CHOP), or R-CHOP-like treatment at Kansai Medical University Hospital during 2006--2014 in this retrospective analysis. This study was approved by the Ethics Committee of Kansai Medical University. Patient survival was analyzed with the Kaplan--Meier method, and results were compared by log-rank and Cox proportional hazards models. *P*\<0.05 was considered significant. All statistical analyses were performed using EZR (modified R software, Saitama Medical Center, Jichi Medical University, Saitama, Japan).

3. Results {#s0015}
==========

Mean age of these patients was 67 years old (range: 20--91 years). The NCCN-IPI classified 11% of patients being as low risk, 36% as low-intermediate (LI), 47% as high-intermediate (HI) and 6% as high risk ([Table 1](#t0005){ref-type="table"}). Compared to the older IPI, fewer patients were classified as low- or high-risk and more as LI and HI. The NCCN-IPI failed to identify four prognostic groups of patients in our cohort. Our patients' 5-year overall survival (OS) rates were low-risk: 80.7%; LI: 74.8%; HI: 55.4%; and high-risk: 67.5% (*P*=0.005) ([Fig. 1](#f0005){ref-type="fig"}.(A)). Their 5-year progression-free survival (PFS) rates were low-risk: 76.8%; LI: 78.6%; HI: 63.7%; and high-risk: 58.3% (*P*=0.0722) ([Fig. 2](#f0010){ref-type="fig"}.(A)). For patients who did not receive upfront autologous hematopoietic stem cell transplantation (ASCT), the 5-year OS rates were low-risk: 80.7%; LI: 76.5%; HI: 53.2%, and high-risk: 63.5% (*P*=0.00137) ([Fig. 1](#f0005){ref-type="fig"}.(B)). Their 5-year PFS rates were low-risk: 76.8%; LI: 80.3%; HI: 58.7%; and high-risk: 63.6% (*P*=0.123) ([Fig. 2](#f0010){ref-type="fig"}.(B)).

In multivariate analysis, low albumin level (\<3.5 g/dl) was an independent predictor of shorter OS, although lactate dehydrogenase (LDH), hemoglobin (Hb), C-reactive protein (CRP), age, sex, stage, extranodal involvement, and ASCT were not ([Table 2](#t0010){ref-type="table"}).

4. Discussion {#s0020}
=============

Although the NCCN-IPI was developed to improve stratification of high-risk patients with DLBCL (i.e., whose 5-year OS\<50%), it failed to detect them in our analysis; the HI group had shorter 5-year OS than the high-risk group ([Fig. 1](#f0005){ref-type="fig"} A.).

In our institute, most eligible high-risk or HI patients were treated with upfront ASCT, which we assumed would improve their survival. When we excluded these patients from our analysis, the poorer 5-year OS for the HI group compared with the high-risk group was even more pronounced ([Fig. 1](#f0005){ref-type="fig"} B.).

As the NCCN-IPI attaches more weight on age in the 4 risk groups, we supposed that its failure to predict outcome in this study was because our patients were older than original cohort; thus prognoses of patients whose high scores were due to age rather than tumor burden (as indicated by LDH or stage) might not be accurately predicted in the NCCN-IPI system. Some reports described results similar to ours, showing that NCCN-IPI failed to accurately predict outcomes for elderly patients [@bib4], [@bib7].

Aside from LDH, information about how other important parameters affect NCCN-IPI results have not been published, as far as we know. Hemoglobin [@bib2], albumin [@bib3], [@bib4], and CRP [@bib5] have been found to be independent prognostic factors in aggressive lymphoma. As these reported parameters were routinely available in our patients' records, we analyzed their effects on OS, using multivariate analysis; however, we found only low albumin levels to be a significant predictor of worse 5-year OS. As albumin is usually assessed, quite easily and cheaply in standard blood laboratory tests, and is highly reproducible, it could be an important predictor, and be incorporated into a prognostic index.

Although the NCCN-IPI is a promising simple scale based on conventional clinical factors, its usefulness remains controversial [@bib6], [@bib7]. It should be evaluated in populations of different regions and ethnicities before adopting it for routine clinical use.

Conflict of interest {#s0025}
====================

The authors declare no competing financial interest in relation to the work.

![Five-year OS using NCCN-IPI were 80.7%, 74.8%, 55.4%, 67.5% (p=0.005) (A). Patients without upfront ASCT(B) were 80.7%, 76.5%, 53.2%, 63.5%(p=0.00137) (B). The result revealed that patients were statistically stratified into 4-risk groups, however HI was the worst prognosis.](gr1){#f0005}

![Five-year PFS using NCCN-IPI were 78.6%, 76.8%, 63.7%, 58.3% (p=0.0722) (A). Patients without upfront ASCT(B) were 80.3%, 76.8%, 58.7%, 63.6%(p=0.123)(B).](gr2){#f0010}

###### 

Patients\' characteristics.

Table 1

  No. of patients (n)          284
  ---------------------------- ------------
  Median age, range(y/o)       67(20--91)
  40≧(%)                       5
  \>40 to ≦60(%)               23
  \>60 to ≦75(%)               49
  \>75 (%)                     23
  Male sex (%)                 61
                               
  IPI/aaIPI (%)                
  Low                          37
  Low-intermediate             16
  High-intermediate            19
  High                         28
                               
  NCCN-IPI (%)                 
  Low                          11
  Low-intermediate             36
  High-intermediate            47
  High                         6
                               
  Stage(%)                     
  Ⅰ                            23
  Ⅱ                            14
  Ⅲ                            19
  Ⅳ                            44
  Elevated LDH level (%)       48
                               
                               
  Extranodal disease \>1 (%)   40
  upfront ASCT(%)              9

LDH: lactate dehydrogenase

ASCT: autologous hematopoietic stem cell transplantation

###### 

Multivariate analysis.

Table 2

  Parameter      HR      95%CI          p value
  -------------- ------- -------------- ---------
  LDH            1.106   0.681--1.793   0.684
  Alb            1.949   1.121--3.386   0.018
  Hb             1.088   0.666--1.775   0.737
  CRP            0.986   0.333--2.912   0.980
  Age            1.177   0.712--1.947   0.525
  Sex            1.325   0.828--2.119   0.241
  Stage          1.642   0.866--3.109   0.128
  extra node     1.526   0.910--2.557   0.109
  upfront ASCT   0.404   0.151--1.073   0.069

LDH: lactate dehydrogenase

Alb: albumin

Hb: hemoglobin

CRP: C-reactive protein

ASCT: autologous hematopoietic stem cell transplantation
